Business Wire

SC-ENVIVA-FOREST-FUND

20.9.2022 18:04:36 CEST | Business Wire | Press release

Share
The Enviva Forest Conservation Fund Announces its 2022 Grant Recipients

The Enviva Forest Conservation Fund (the Fund) today announced the recipients of its 2022 grants. The projects funded this year will help conserve more than 3,000 acres and protect ecologically sensitive bottomland hardwood forests in the Virginia-North Carolina coastal plains.

Including those announced today, the Fund has awarded 29 projects totaling more than $3,100,000 in grants over the past seven years. An estimated 33,000 acres will be protected when these projects reach completion. The forests conserved as a part of the Fund help clean drinking water, purify the air, buffer structures from storms, and provide habitat for many species of wildlife, while at the same time, providing jobs and economic opportunity for rural families and private landowners.

“The fund is well on its way to achieving its initial goal to protect over 35,000 acres of sensitive bottomland hardwood forests across Virginia and South Carolina,” said Thomas Meth, President of Enviva. “With more than three years left in the program, the Fund is poised to partner with more and more diverse conservation groups as well as supersede our commitment to long-term investments in forest stewardship for generations to come.”

The 2022 Enviva Forest Conservation Fund grant recipients include:

The Tar River Land Conservancy: Tar River Land Conservancy aims to purchase the Bowers Tract, consisting of 244 forested acres and 60 acres of agricultural upland fields. Fifty-four percent (219 acres) of the property is situated within the 100-year-old floodplain of Swift Creek, a major tributary of the Tar River. Adjoining the property, Swift Creek provides a habitat for numerous rare, threatened, and endangered aquatic species, including the federally protected Carolina Madtom, Tar River Spiny Mussel, and Neuse River Waterdog.

Three Rivers Land Conservancy: Three Rivers Land Conservancy aims to acquire 440 acres of bottomland hardwood forest adjacent to the Little River and Uwharrie National Forest in Montgomery County, North Carolina. The Little River Buffer and Cliffs natural areas are located on the property. Federally endangered Northern Long Eared Bat and the threatened Oak Toad, Alewife, and Blue Back Herring are all present within this forest acreage.

The Virginia Outdoors Foundation: The Virginia Outdoors Foundation aims to acquire the Turner Tract which lies on the state scenic Nottoway River near Cary's Bridge. This tract contains 134 acres of bottomland hardwoods (111 acres of general hardwoods and 23 acres of Cypress-Tupelo) which will be designated as "old growth" as well as hundreds of acres of working forest. This land contributes to the protected corridor on the Nottoway River and its conservation will support the effort to protect this unique and fragile Virginia resource with a “National Wild and Scenic River” designation. The balance of the tract will remain in working forest and/or agricultural use.

The Conservation Fund: The Conservation Fund will protect 1,915 acres dominated by native bottomland hardwoods, forested wetlands, and loblolly pine along the Nottoway River in Sussex County, Virginia. This project will add to the corridor of protected land along the Nottoway River with 3.5 miles of frontage along the Nottoway where federally endangered Roanoke Logperch and Dwarf Wedge Mussel are found. The property also features 2.5 miles of frontage on Black Branch Swamp, where over 220 acres of forested wetlands and 400 acres of bottomland hardwoods reside. Sustainable forest management and restoration to native longleaf pine and pine savanna on the property will help create a habitat for endangered species such as the Red-Cockaded Woodpecker. Once transferred to the Virginia Department of Wildlife Resources, the property will be open for hunting, hiking, fishing, boating, and wildlife watching.

Ducks Unlimited: Ducks Unlimited aims to acquire a total of 292 acres in Bertie and Gates counties in North Carolina, under two separate tracts - the Crawford Tract and the Gasking Swamp Tract. The Crawford Tract is home to the Red-Cockaded Woodpecker and will expand the adjacent (on 3 sides) Chowan Swamp Game Land, which is located in one of the most important river basins for anadromous fishes in North Carolina. The Gasking Swamp Tract will expand the adjacent Bertie County Game Land, which helps protect portions of the Cashie River Swamps’ small creeks, floodplain wetlands, and Significant Natural Heritage Areas. These tracts provide important travel corridors for black bears along the Cashie River and are recognized as a “Global Important Bird Area.”

“The Endowment continues to support the efforts of the Enviva Forest Conservation Fund. These long-term investments promote conservation, biological diversity, and ecosystem sustainability in these areas of North Carolina and Virginia,” said Teal Edelen, Program Officer at the U.S. Endowment for Forestry and Communities. “These grants support sources of clean air and water, protect threatened wildlife and plant life, and provide great opportunities for recreation in these areas.”

About the Enviva Forest Conservation Fund
The Enviva Forest Conservation Fund is a $5 million, 10-year program established by Enviva in December 2015 to protect environmentally sensitive bottomland and wetland forests. Administered by the U.S. Endowment for Forestry and Communities, the Fund awards grants annually to nonprofit organizations and government agencies for conservation projects. Learn more at http://envivaforestfund.org.

About the U.S. Endowment for Forestry and Communities
The U.S. Endowment for Forestry and Communities is a not-for-profit public charity working collaboratively with partners in the public and private sectors to advance systemic, transformative, and sustainable change for the health and vitality of the nation’s working forests and forest-reliant communities. To learn more about the Endowment, please visit our website at www.usendowment.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920006011/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye